In this issue:
Is pelvic MRI the most accurate way to stage localised rectal cancer?
Real-world use of PPRT in US patients with gastroenteropancreatic NETs
FOLFOX demonstrates activity in aggressive heavily pre-treated pancreatic NETs
Wild-type APC is prognostic for inferior survival in metastatic MMS CRC
Front-line panitumumab may be a therapeutic option for frail elderly patients with left-sided CRC
No benefit to the addition of afatinib to gemcitabine for metastatic PAC
Analysis of RAINBOW shows that tumour response associates with improvements in QoL
Trifluridine/tipiracil plus ramucirumab in previously treated advanced gastric cancer
Blood type B is a risk factor for drug-induced ILD in pancreatic cancer
Axitinib not suitable for use in unselected gemcitabine-refractory biliary tract cancer
Please login below to download this issue (PDF)